ASH 2019: Multiple Myeloma
Filter Results
Understanding Multiple Myeloma Outcomes Based on Comorbidities & Race
A recent study highlighted the treatment disparities that exist among black multiple myeloma patients treated in the Veterans Health Administration (VHA), despite improved mortality compared to their non-black counterparts.
Study Assesses Outcomes in Patients With t(11;14) Multiple Myeloma
Multiple myeloma is a heterogeneous malignancy, with individuals having disease that can display a wide array of genetic abnormalities.
REGN5458 (BCMAxCD3) Shows Positive Preliminary Results in Multiple Myeloma
Initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma were presented at the 2019 ASH Annual Meeting.
Positive Results for Isatuximab-Pomalidomide-Dexamethasone Combo in Heavily Pre-Treated Multiple Myeloma
For patients with multiple myeloma, previous clinical studies have shown that deep responses have been associated with improvements in outcomes such as progression-free survival (PFS) and overall survival (OS).
Novel NK- & T Cell-Based Therapy Programs for Multiple Myeloma
Data introducing an extensive platform in genetically-modified NK- and T cell-based programs, and highlighting long-term safety and efficacy results from the phase I study of PNK-007 in patients with multiple myeloma, were announced at the 2019 ASH Annual Meeting.
NK Cell-Based Therapy for Multiple Myeloma & Non-Hodgkin Lymphoma
Updated results from a phase I clinical study of GDA-201, an investigational, natural killer (NK) cell-based cancer immunotherapy for the treatment of patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) were revealed at the 2019 ASH Annual Meeting.
The ICARIA-MM Trial: Efficacy Data for Isatuximab With Pomalidomide & Dexamethasone
Multiple myeloma is frequently diagnosed in patients aged 65 years or older.
The Global State of HSCT & Disease Burden for Patients With Multiple Myeloma
In a new analysis of a retrospective survey conducted annually between 2006 and 2015, researchers sought to better characterize utilization of stem cell transplantation (SCT) for patients with multiple myeloma at Worldwide Network for Blood & Marrow Transplantation regions around the globe.
Updated Data From the Phase II HORIZON Study in Patients With RRMM
Researchers provided the final update on data from the phase II HORIZON (OP-106) trial evaluating melflufen in relapsed/refractory multiple myeloma at the 2019 ASH Annual Meeting (Abstracts 1883, 3487, 3124, 3163, 1839).